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Abstract 
The dog is an important species used in preclinical studies in support of human drug product 
development. Likewise, because of the many active pharmaceutical ingredients (APIs) with therapeutic 
relevance to both humans and dogs, extrapolation can also occur in the reverse, from human to dog. In 
either situation, it is important to appreciate species-specific factors influencing drug pharmacokinetics 
(absorption, metabolism, disposition, and elimination) and the potential impact of disease on the 
applicability of these extrapolations. Furthermore, tools such as physiologically based pharmacokinetic 
(PBPK) models not only enable investigators to extrapolate species-specific data on systemic or organ 
exposure to the parent compound and metabolite(s) but also facilitates an interrogation of factors that 
can lead to species-specific differences in drug effectiveness and toxicity. In this review, we explore the 
factors and tools that comprise our current arsenal for understanding and predicting human-canine 
comparative toxicity. 
Keywords 
Dog-Human Toxicology, Dog-Human Shared Diseases, Interspecies Extrapolation, PBPK Models 
Disciplines 
Medical Toxicology | Small or Companion Animal Medicine | Veterinary Toxicology and Pharmacology 
Comments 
This is a manuscript of an article published as Martinez, Marilyn N., Jonathan P. Mochel, and Devendra 
Pade. "Considerations in the Extrapolation Drug Toxicity Between Humans and Dogs." Current Opinion in 
Toxicology (2020). DOI: 10.1016/j.cotox.2020.05.005. 
This article is available at Iowa State University Digital Repository: https://lib.dr.iastate.edu/bms_pubs/87 
Journal Pre-proof
Considerations in the Extrapolation Drug Toxicity Between Humans and Dogs




To appear in: Current Opinion in Toxicology
Received Date: 12 March 2020
Accepted Date: 28 May 2020
Please cite this article as: M.N. Martinez, J.P. Mochel, D. Pade, Considerations in the Extrapolation
Drug Toxicity Between Humans and Dogs, Current Opinion in Toxicology, https://doi.org/10.1016/
j.cotox.2020.05.005.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.








Sensitivity to Toxicity of 
Drug and/or Metabolites





Considerations in the Extrapolation Drug Toxicity Between Humans and Dogs  
 
Marilyn N. Martinez1*†, Jonathan P. Mochel2, Devendra Pade3 
1. Office of New Animal Drug Evaluation, Center for Veterinary Medicine, Food 
and Drug Administration, Rockville, Maryland  20855 
marilyn.martinez@fda.hhs.gov 
2. Department of Biomedical Sciences, Iowa State Univers ty, Ames, Iowa, 50011, 
USA. jmochel@iastate.edu. 
3. Certara UK Limited, Simcyp Division, 1 Concourse Way, Sheffield S1 2BJ, 
United Kingdom. devendra.pade@certara.com  
 
* Communicating Author  
†This work reflects the opinions of the authors anddoes not reflect the represent the view 




The dog is an important species used in preclinical studies in support of human drug 
product development. Likewise, because of the many active pharmaceutical ingredients 
(APIs) with therapeutic relevance to both humans and dogs, extrapolation can also occur 
in the reverse, from human to dog. In either situation, it is important to appreciate 
species-specific factors influencing drug pharmacokinetics (absorption, metabolism, 
disposition, and elimination) and the potential impact of disease on the applicability of 
these extrapolations. Furthermore, tools such as phy iologically based pharmacokinetic 
(PBPK) models not only enable investigators to extrapolate species-specific data on 
systemic or organ exposure to the parent compound and metabolite(s) but also facilitates 
an interrogation of factors that can lead to species-specific differences in drug 
effectiveness and toxicity. In this review, we explore the factors and tools that comprise 




In 2013, it was estimated that 90,000 dogs/annum were used in scientific research in the 
United States (US) + European Union (EU), with about 80% of this use being related to 
preclinical studies (as the non-rodent mammalian species) for evaluation of drug toxicity 
and effectiveness [1]. Although the occurrence of toxicity in dogs was associated with a 
high likelihood of the presence of human drug toxicity (based upon the FDA Adverse 
Event Reporting System for 2366 FDA-approved human compounds), the 
expression/organ system associated with that toxiciy was not highly correlated [1]. 
Conversely, the finding of no toxicity in the dog did not assure the absence of human 
drug toxicity. Interestingly, another study based on preclinical data generated in rodent 
and non-rodent species noted that of the 93 human adverse drug reactions (ADRs) 
associated with 43 small molecule drugs in the EU, only 19% of the toxicities were 
identified during the preclinical studies [2]. Although the latter is not limited to dogs, 
experience with prior failures to identify human ADRs underscores potential challenges 
associated with efforts to employ interspecies extrapolation for prediction of drug 
toxicity.  
 
With regard to the latter conclusion, an important point to note is that these published 
assessments exclude those drugs not progressing to market may lead to an over-
estimation of the error associated with the prediction of human ADRs from animal model 
data  [3]. Nevertheless, these assessments are consistent with drugs that pass preclinical 
tests and later move on to fail in clinical trials for which an estimated 92-94% are largely 
due to unforeseen toxicities. These kinds of statistics lead some investigators [4] to 
remain consistent in their conclusion that public information does not support claims that 
canine toxicity studies can reliably predict human drug safety, toxicity or effectiveness.  
 
Clark [5] also comments on the importance of considering false negatives. Using a 
likelihood ratio, he observed that while the precipitation of cardiac arrhythmias, liver 
damage and renal failure in animals were highly indicative of the likelihood of a similar 
event in humans, the lack of canine toxicity did not share the same prognostic value. In 
fact, most compounds for which there were post approval clinical findings (leading to 
either relabeling or product withdrawal) did not exhibit a corresponding toxicity in 
animals. Of note was the low animal vs human frequency of QT prolongation, the onset 
of jaundice, abnormal hepatic function, renal failure and impairment, or hepatitis. The 
question is whether this reflects a lack of toxicity in the animal model or rather the very 
small number of animals challenged relative to the thousands of human patients that will 
be exposed to the drug. 
 
Similarly, although canine Torsade de Pointe is rare, there are examples of similar 
human-dog response to drug-induced QT prolongation. H wever, the human vs canine 
mechanism of this effect appears to differ. QTc changes are potentially induced by 
changes in the potassium channel or the sodium-calcium urrents. However, the ion 
channel responsible for that change appears to differ in humans vs dogs. This conclusion 
was reached upon examining the ECG changes associated with the administration of 
several compounds known to induce ion channel inhibtion and ECG changes in humans 
[6], including dofetilide, sotalol, verapamil, and cisapride.  
 
The IQ consortium evaluated the first-in-human safety translation of safety data from 
preclinical species to humans [7]. Considering 182 molecules, they evaluated the positive 
predict value (PPV: the proportion of positive nonclini al findings that had positive 
clinical findings), negative predict value (NPV: the proportion of negative nonclinical 
findings that had negative clinical findings), sensitivity (the proportion of positive clinical 
findings that had positive nonclinical finding) and the reduction in uncertainty in human 
drug safety as a function of data generated in the specific preclinical species (or 
combination of preclinical species). The drugs used in this evaluation were known to 
exhibit adverse outcomes in humans. The proportion of PPV, NPV and the sensitivity of 
the human-canine comparison as a function of organ systems is provided in Figure 1.  
 
INSERT FIGURE 1 
 
As a general rule, a test is considered “diagnostic” in predicting a positive outcome when 
the LR+ is ≥10 or for predicting a negative outcome when the iLR− is ≥10. For dogs, 
there was a 40% reduction in uncertainty in human drug safety for adverse reactions as it 
pertains to the CNS and a 28% reduction for GI toxicity. For hepatotoxicity, the dog had 
approximately 40% false positives (i.e., demonstrated toxicity when none occurred in the 
humans). The corresponding drug exposure for false po itive reactions occurred largely at 
doses >5-fold that of the human, although some were at lower total drug exposure. Of 
course, the possibility of differences in active metabolites were not considered but could 
have influenced this outcome. Furthermore, within any species, there are polymorphisms 
(particularly as it pertains to metabolism and transporter activity) that can affect drug 
effectiveness or safety [e.g., 8, 9, 10].  
 





The challenges associated with interspecies extrapolations apply not only to extrapolating 
dog to human but also human to dog. For instance, there are foods typically innocuous in 
humans that are potentially toxic in dogs (Table 1).  
  
 
Table 1: Example of foods that are non-toxic in humans but toxic to dogs 




Clinical signs of chocolate toxicosis usually occur within 
6–12 hr of ingestion. Initial signs may include 
polydipsia, vomiting, diarrhea, abdominal distentio, and 
restlessness. Signs may progress to hyperactivity, 
polyuria, ataxia, rigidity, tremors, and seizures. 
11,12,13,14  
Citrus fruits Due to the psoralen compounds and the aromatic oils, 
oranges, lemons, limes, etc. can lead to irritation of the 
canine digestive track and cause central nervous system 
(CNS) depression if consumed in large quantities. 
13,15  
Coconut Contains high levels of potassium and medium chain 
triglycerides that can lead to GI upset and diarrhea. 13  
Grapes and 
raisins 
Although specific toxic substance has not been 
identified, consumption of grapes and raisons can le d to 





Some nuts are less toxic than others, and some (e.g., 
peanuts and small quantities of peanut butter) are 
typically safe. However, digestibility of nuts can be an 
issue, leading to vomiting, diarrhea and pancreatitis. 
13,14,17 
Xylitol Liver failure and by inducing high levels of insulin 
release, hypoglycemia and seizures. 13,14 
Milk and dairy Because many dogs are lactose intolerant, digestive 





Onions, garlic, leeks and chives contain N-propyl 
disulfide which reduces the activity of glucose-6-
phosphate dehydrogenase in red blood cells; thereby 
interfering with regeneration of reduced glutathione 
needed to prevent oxidative denaturation of hemoglobin. 
Interestingly, it is not without impact in humans and if 




In addition, some human medications can be highly toxic (e.g., acetaminophen, 
ibuprofen, naproxen and as well as several other pha maceutical agents) or lead to 
unexpected paradoxical effects (e.g., alprazolam or zolpidem) when used in dogs. [20].  
  
Extrapolation failure may also reflect dog-human differences in the formation of a toxic 
metabolite. For example, the plasticizer, Di(2-ethylhexyl) phthalate (DEHP) is rapidly 
metabolized to mono(2-ethylhexyl)phthalate (MEHP), an active metabolite. While 
neither human nor dogs hydrolyzed DEHP to MEHP in the intestine, substantial 
conversion occurred in the liver. In that regard, this conversion was 4.6-fold greater in 
dogs than humans. This markedly higher efficiency of conversion of DEHP to MEHP in 
dogs than humans is probably a reason for the greater toxicity of this plasticizer in dogs 
than humans [21].  
 
Another example of extrapolation failure reflects differences in transporter activity. For 
example, dogs are particularly susceptible to the toxicity of the herbicides, phenoxyacetic 
acids and related organic acids, relative to that observed in other species [22]. This 
greater sensitivity has been linked with the dog’s lower capacity to secrete organic acids 
from the kidney as compared to humans. This translates to a T½ difference for two 
phenoxyacetic acids, 2,4-dichlorophenoxyacetic acid(2,4-D) and 4-chloro-2-
methylphenoxyacetic acid (MCPA) of 92–106 and 63 h, respectively, in dogs versus 12 
and 11 h, respectively, in humans.  
 
Thus, from a pharmacokinetic perspective, variables that can contribute to human-canine 
PK and toxicity differences include: 
 
• Enzymatic conversion (Phase 1 and 2) [23,24,25,26,27,28,29] 
• Hepatic transporters [8,30,31,32] 
• Renal transporters [22,33,34,35,36] 
• Gut microbiome [37,38,39] 
• Protein binding/volume of distribution [31,40,41,423] 
 
The Value of Spontaneous Animal Disease Models to Characterize Drug Safety and 
Activity 
 
Failure of accurately describing product safety andeffectiveness in human patients [1] is 
particularly problematic in the neurosciences [44] and oncology [45] where these 
estimates are closer to 95%. These high attrition rates in Phase II/III clinical programs 
stem partly from toxicity characterization being performed in healthy animals, thereby 
ignoring the impact of disease state on drug pharmacokinetics and pharmacodynamics 
[44,45,46,47,48,49,50,51,52,53]. There is, therefore, a critical need to incorporate the 
effect of disease on candidate drug safety and effectiveness early in the drug research and 
development lifecycle. That objective can be achieved by using spontaneous animal 
disease models. In that regard, pet dogs and humans sh re numerous analogous clinical 
diseases, including cancer, inflammatory bowel disease (IBD), diabetes and cognitive 
dysfunction. For instance, canine cognitive dysfunctio  (CCD) is the only naturally 
occurring mammalian dementia to mimic Alzheimer’s Di ease, with striking clinical 
similarities to the human analog [54,55]. Similarly, as opposed to genetically-modified 
murine models, cancers develop spontaneously in dogs [56,57] 
 
In an effort to characterize the oral absorption and gastrointestinal safety of orally 
administered drugs, 3-dimenstional (3D) intestinal organoids have been developed from 
intestinal crypts obtained via endoscopic biopsies [58]. Recent findings show that 3D 
intestinal organoids can be successfully maintained from healthy dogs and dogs with 
naturally occurring IBD. These in vitro systems can potentially serve as a relevant 
preclinical model for drug testing prior to live animal studies [59,60,61]  
 
Use of Mechanistic PBPK Models to Support Interspecies Extrapolation.  
 
It is well known that for orally administered drugs, bioavailability studies in animals 
cannot quantitatively predict human drug bioavailability [62]. Some of the factors that 
may be confounding this correlation between animals (single or combined species) and 
human are the differences in (i) drug metabolizing e zymes, (ii) drug transporters, (iii) 
anatomy and physiology of the GI tract, (iv) plasma protein binding, etc. Therefore, 
animal models that take into consideration species sp cific factors affecting drug 
bioavailability are recommended to enable quantitative predictions [62, 63]. PBPK 
models take into consideration species specific anatomy and physiology in combination 
with drug data (physicochemical, solubility, permeability, distribution and elimination). 
These are linked with an i vitro-in vivo extrapolation (IVIVE) to quantitatively predict 
drug pharmacokinetics in that animal species [64]. During early drug development, from 
discovery to first – in – human, in vitro drug data are limited. However, the amount of 
available information increases as the product progresses through the different stages of 
development. PBPK platforms, combined with IVIVE techniques, are positioned to 
incorporate and utilize these experimental data as they become available [65]. In so 
doing, the PBPK models can greatly enhance the information derived from that early 
data.  
 
An approach towards using PBPK models for interspecies extrapolation is shown in 




A successful cross species translation to human for the pharmacokinetics of a drug cannot 
be guaranteed and largely depends on the type of drug being investigated. The probability 
of a successful translation (pharmacokinetic parameters within 2-fold of observed) can be 
maximized using reliable species-specific drug parameters (such as fraction unbound in 
plasma, blood to plasma ratio, fraction unbound in the microsomes, etc) in the relevant 
PBPK models. Drug input parameters that are intrinsic i  nature should be identified 
(such as intrinsic solubility, intrinsic transcellular permeability, bile partitioning 
coefficient, etc.) and verified using in vitro experiments [66,67,68]. In certain cases, 
allometric scaling can be coupled with animal PBPK models to predict the 




Given the frequency of parallel drug development and increasing availability of in vitro 
tools to support PK understanding, and the advancements in in silico systems to have the 
dog and human physiological (population) models for prediction of in vivo parent and 
metabolite exposure, there is the potential to expect tr mendous progress in our ability to 
extrapolate drug toxicity between humans and dogs. A realization of this potential 
depends upon the willingness of the scientific communities to utilize these tools and 
dialogue on shared opportunities for filling existing holes. Ultimately, it will be through 
that effort that we can greatly increase the efficien y of our predictions. 
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Figure 1: Assessment of the extrapolation between human and dog toxicity across various organ 
systems. Based upon information from [7]. Sen (%) = sensitive percent (the proportion of 
positive clinical findings that had positive non findings; PPV = predictive positive value (the 
proportion of positive nonclinical findings that had positive clinical findings), NPV = negative 
predictive value (the proportion of negative clinical findings that had negative clinical values), 
LR = likelihood positive ratio ( the increase in odds of a positive clinical finding that is due to 
the knowledge of a positive nonclinical finding); iLR- = Inverse likelihood ratio negative (the 
increase in odds of a negative clinical finding that is due to the knowledge of a negative 
nonclinical finding). Values estimated as a ratio of the True Positive and True Negative number 
of observations divided the total number of observations associated with positive or negative 
outcomes. All parameter values are expressed within a range of 0 to 100. 
 
Figure 2: Potential mechanisms underlying dog-human differences in drug toxicity. 
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Figure 2: Potential mechanisms underlying dog-human differences in drug toxicity.

Figure 3: General workflow of inter species extrapolation to human 
using PBPK models
Declaration of interests 
 
☐ The authors declare that they have no known competing financial interests or personal relationships 
that could have appeared to influence the work reported in this paper. 
 
☒The authors declare the following financial interests/personal relationships which may be considered 






Dr. Martinez is a Senior Scientist with the US Food and Drug Administration has no competing financial 
interests or personal relationships that could have appeared to influence the work reported in this paper. 
Dr. Mochel is a co-founder of 3D Health Solutions, a startup company that develops 3D canine organoids 
for drug testing purposes. 
Dr. Pade is a scientific expert employed by Certara UK, for the Simcyp PBPK Modeling and Simulation 
Software 
 
